Showing 4991-5000 of 5910 results for "".
- Analysis: Ambulatory Surgery Centers Reduce Medicare Costs by More than $4 Billion Each Yearhttps://modernod.com/news/analysis-ambulatory-surgery-centers-reduce-medicare-costs-by-more-than-4-billion-each-year/2478306/New analysis of Medicare payment data shows that ambulatory surgery centers (ASC) reduced Medicare costs by $28.7 billion from 2011 through 2018 by providing services to beneficiaries that otherwise would have been provided in higher-cost hospital outpatient departments (HOPD), according to the A
- Moody’s: Hospital Financial Outlook Worse as COVID-19 Relief Funds Start to Dwindlehttps://modernod.com/news/moodys-hospital-financial-outlook-worse-as-covid-19-relief-funds-start-to-dwindle/2478308/For-profit hospitals are expected to see a financial decline over the next 12 to 18 months as federal relief funds that shored up revenue losses due to COVID-19 start to wane, a recent analysis from Moody’s said, according to a FierceHealthcare
- Rayner to Launch RayOne EMV Enhanced Monofocal IOLhttps://modernod.com/news/rayner-to-launch-rayone-emv-enhanced-monofocal-iol/2478303/Rayner has announced the upcoming European launch of RayOne EMV, a new fully preloaded non-diffractive IOL designed to enhance patient outcomes achieved with monovision. Developed in collaboration with Professor Graham Barrett, president of the Australasian Society of Cata
- Liminal BioSciences Provides Update on Progress on BLA for Ryplazim (Plasminogen)https://modernod.com/news/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen/2478301/Liminal BioSciences announced that the FDA acknowledged receipt of the resubmission of the Biologic License Application (BLA) for Ryplazim (plasminogen) for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency (C-PLGD) in pediatrics and adults. The
- Neuro-Optometric Rehabilitation Association Announces Appointments of New Executive and Advisory Board Officershttps://modernod.com/news/neuro-optometric-rehabilitation-association-announces-appointments-of-new-executive-and-advisory-board-officers/2478297/The Neuro-Optometric Rehabilitation Association (NORA) announced the appointments of its new executive and advisory board members. DeAnn Fitzgerald, OD, assumes the position of President, succeeding Susan Daniel, OD, who now joins the NORA Advisory Board. Dr. Fitzgerald has been providing
- Oxford Says AstraZeneca Trial Illnesses May Not Be Linked to COVID-19 Vaccinehttps://modernod.com/news/oxford-says-astrazeneca-trial-illnesses-may-not-be-linked-to-covid-19-vaccine/2478290/Neurological symptoms developed by some volunteers in a trial testing AstraZeneca’s COVID-19 vaccine candidate AZD1222 either probably did not come about as a result of the vaccine, or there is not enough evidence to say one way or the other, according to the University of Oxford. The discl
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey
- Facebook and EssilorLuxottica Announce Collaboration for Smart Glasseshttps://modernod.com/news/facebook-and-essilorluxottica-announce-collaboration-for-smart-glasses/2478288/Facebook and EssilorLuxottica announced a multiyear collaboration to develop the next generation of smart glasses. The announcement was made by Mark Zuckerberg during Facebook Connect, an annual conference held virtually from California. Terms of the deal were not disclosed. The par
- GenSight Biologics Submits EU Marketing Authorization Application for LHON Gene Therapy Lumevoqhttps://modernod.com/news/gensight-biologics-submits-eu-marketing-authorization-application-for-lhon-gene-therapy-lumevoq/2478287/GenSight Biologics announced that it has submitted the Marketing Authorization Application (MAA) for its lead product Lumevoq to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation
- Recordati Rare Diseases Announces Availability of Cystadrops in the UShttps://modernod.com/news/recordati-rare-diseases-announces-availability-of-cystadrops-in-the-us/2478283/Recordati Rare Diseases announced that Cystadrops (cysteamine ophthalmic solution) 0.37% is now available for prescription and distribution across the United States. Cystadrops is a new, viscous eye drop solution that depletes cystine crystal deposits in the corne